Get the latest tech news
Gilead’s twice-yearly shot to prevent HIV succeeds
Gilead's experimental twice-yearly medicine to prevent HIV was 100% effective in a late-stage trial, the company said Thursday.
The results bring Gilead one step closer to introducing a new form of pre-exposure prophylaxis, or PrEP, and broadening its HIV business. "It's really important to have more options than daily pills because the orals aren't going to get us to the end of the epidemic," said Bruce Richman, founding executive director of the nonprofit Prevention Access Campaign. RBC Capital Markets analyst Brian Abrahams expects Gilead's shot will significantly increase the number of people interested in preventive HIV medicine.
Or read this on r/technology
